CORT Corcept Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CORT
Price (delayed)
$68.2
Market cap
$7.23B
P/E Ratio
53.7
Dividend/share
N/A
EPS
$1.27
Enterprise value
$7.15B
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®
Highlights
The revenue rose by 31% year-on-year
The gross profit is up by 31% year-on-year
CORT's net income is up by 13% YoY but it is down by 5% QoQ
The EPS has grown by 10% year-on-year but it has declined by 6% since the previous quarter
The P/E is 83% more than the 5-year quarterly average of 29.3 and 14% more than the last 4 quarters average of 47.0
The quick ratio is down by 45% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of CORT
Market
Valuations
Earnings
Shares outstanding
106.04M
Market cap
$7.23B
Enterprise value
$7.15B
Price to earnings (P/E)
53.7
Price to book (P/B)
10.53
Price to sales (P/S)
10.36
EV/EBIT
65.37
EV/EBITDA
64.42
EV/Sales
10.43
Revenue
$685.45M
Gross profit
$674.7M
Operating income
$110.87M
Net income
$132.49M
EBIT
$109.36M
EBITDA
$110.98M
Free cash flow
$177.16M
Per share
Balance sheet
Liquidity
EPS
$1.27
EPS diluted
$1.15
Free cash flow per share
$1.7
Book value per share
$6.48
Revenue per share
$6.58
TBVPS
$8.13
Total assets
$846.46M
Total liabilities
$163.17M
Debt
$6.84M
Equity
$683.29M
Working capital
$295.44M
Debt to equity
0.01
Current ratio
3.07
Quick ratio
2.69
Net debt/EBITDA
-0.75
Margins
Efficiency
Dividend
EBITDA margin
16.2%
Gross margin
98.4%
Net margin
19.3%
Operating margin
16.2%
Return on assets
16.6%
Return on equity
20.4%
Return on invested capital
19.7%
Return on capital employed
15.5%
Return on sales
16%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CORT stock price
How has the Corcept Therapeutics stock price performed over time
Intraday
-1.37%
1 week
-1.27%
1 month
-6.86%
1 year
86.7%
YTD
35.34%
QTD
-7.08%
Financial performance
How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$685.45M
Gross profit
$674.7M
Operating income
$110.87M
Net income
$132.49M
Gross margin
98.4%
Net margin
19.3%
The revenue rose by 31% year-on-year
The gross profit is up by 31% year-on-year
The operating margin has contracted by 30% YoY and by 20% from the previous quarter
Corcept Therapeutics's operating income has decreased by 19% from the previous quarter and by 9% YoY
Price vs fundamentals
How does CORT's price correlate with its fundamentals
Growth
What is Corcept Therapeutics's growth rate over time
Valuation
What is Corcept Therapeutics stock price valuation
P/E
53.7
P/B
10.53
P/S
10.36
EV/EBIT
65.37
EV/EBITDA
64.42
EV/Sales
10.43
The P/E is 83% more than the 5-year quarterly average of 29.3 and 14% more than the last 4 quarters average of 47.0
The EPS has grown by 10% year-on-year but it has declined by 6% since the previous quarter
The stock's price to book (P/B) is 70% more than its 5-year quarterly average of 6.2 and 9% more than its last 4 quarters average of 9.7
The company's equity rose by 25% YoY
CORT's P/S is 46% above its 5-year quarterly average of 7.1 and 8% above its last 4 quarters average of 9.6
The revenue rose by 31% year-on-year
Efficiency
How efficient is Corcept Therapeutics business performance
CORT's ROIC is down by 43% year-on-year and by 27% since the previous quarter
The return on sales has declined by 31% year-on-year and by 20% since the previous quarter
The return on equity has declined by 16% year-on-year and by 10% since the previous quarter
CORT's return on assets is down by 15% year-on-year and by 11% since the previous quarter
Dividends
What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CORT.
Financial health
How did Corcept Therapeutics financials performed over time
The total liabilities has soared by 51% YoY
The quick ratio is down by 45% year-on-year and by 14% since the previous quarter
Corcept Therapeutics's debt is 99% lower than its equity
The company's equity rose by 25% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.